Myelodysplastic Syndrome Clinical Trial

Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Summary

The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Adults with primary or secondary relapsed and/or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Detectable levels of cluster of differentiation 33 (CD33) expression.
Failed alternative therapies with established benefit.
Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and adequate organ function.

Exclusion Criteria:

Acute Promyelocytic Leukemia.
Clinically active central nervous system leukemia.
Active malignant solid tumor.
Pregnant or breastfeeding.
Other protocol-defined inclusion/exclusion criteria apply.

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 1

Estimated Enrollment:

35

Study ID:

NCT06419634

Recruitment Status:

Not yet recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

Local Institution - 0011
New Haven Connecticut, 06510, United States More Info
Site 0011
Contact
Local Institution - 0010
Chicago Illinois, 60611, United States More Info
Site 0010
Contact
Local Institution - 0007
Boston Massachusetts, 02114, United States
Local Institution - 0014
Boston Massachusetts, 02114, United States More Info
Site 0014
Contact
Local Institution - 0013
Saint Louis Missouri, 63110, United States
Local Institution - 0008
Hackensack New Jersey, 07601, United States More Info
Site 0008
Contact
Columbia University Irving Medical Center
New York New York, 10032, United States
Local Institution - 0006
Houston Texas, 77030, United States More Info
Site 0006
Contact
Local Institution - 0009
Fairfax Virginia, 22031, United States
Local Institution - 0002
Toronto Ontario, M5G 2, Canada More Info
Site 0002
Contact
Local Institution - 0003
Montreal Quebec, H3T 1, Canada More Info
Site 0003
Contact

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 1

Estimated Enrollment:

35

Study ID:

NCT06419634

Recruitment Status:

Not yet recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.